Anti-CD28 humanized antibodies
US9562098B2 · kind B2 · utility
2Cited by
2References
12Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 8, 2014 |
| Grant date | Feb 7, 2017 |
| Priority date | — |
| Expiry date | Jan 4, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to humanized antibodies directed against the human lymphocyte receptor CD28. When used in a monovalent form these antibodies are antagonists, i.e. capable of blocking of the CD28/B7 interaction, without activating CD28. These antibodies can be used in particular as therapeutic agents for blocking T cell activation through the CD28 receptor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.